New drug combo aims to hunt down hidden cancer after treatment
NCT ID NCT07136077
Summary
This study is testing whether a combination of two drugs, fruquintinib and tislelizumab, can help control colorectal cancer in patients who have finished their initial chemotherapy but still have tiny amounts of cancer left in their body, detected by a special blood test. The goal is to see if this treatment can clear these hidden cancer cells and prevent the cancer from coming back. It is for patients with a specific type of colorectal cancer who have no visible tumors on scans but have a positive blood test result.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.